VERICEL CORPORATION Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount
VERICEL CORPORATION (VCEL) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount of -$6.55 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-27.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2025-02-27
- VERICEL CORPORATION effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2024 was -$6.55M.
- VERICEL CORPORATION effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2023 was -$586.00K, a 150.17% decline from fiscal 2022.
- VERICEL CORPORATION effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2022 was $1.17M.
- VERICEL CORPORATION effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2021 was -$4.31M, a 1086.50% decline from fiscal 2020.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount 12 month |
|---|---|
| 2024-12-31 | -$6.55M 10-K · filed 2025-02-27 |
| 2023-12-31 | -$586.00K 10-K · filed 2025-02-27 |
| 2022-12-31 | $1.17M 10-K · filed 2025-02-27 |
| 2021-12-31 | -$4.31M 10-K · filed 2024-02-29 |
| 2020-12-31 | $437.00K 10-K · filed 2023-02-23 |
| 2019-12-31 | -$1.33M 10-K · filed 2022-02-24 |
| 2018-12-31 | -$605.00K 10-K · filed 2021-02-24 |
| 2017-12-31 | $563.00K 10-K · filed 2020-02-25 |
| 2016-12-31 | $549.00K 10-K · filed 2019-02-26 |
| 2015-12-31 | $543.00K 10-K · filed 2018-03-05 |
| 2014-12-31 | $48.00K 10-K · filed 2017-03-13 |
| 2013-12-31 | $81.00K 10-K · filed 2016-03-14 |
| 2012-12-31 | $872.00K 10-K · filed 2015-03-25 |
| 2011-12-31 | $1.56M 10-K · filed 2014-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |